Clinical Trial Update: Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

Phase 2 extension study of talampanel for amyotrophic lateral sclerosis was terminated. The trial did not proceed further according to its status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Talampanel (talampanel)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: TERMINATED